相关实验视频
Updated: Jul 24, 2025

09:41
Comprehensive Autopsy Program for Individuals with Multiple Sclerosis
Published on: July 19, 2019
11.5K
在神经病学中死亡的医疗援助
1Department of Psychiatry, Center for Bioethics and Health Humanities, University of Utah, 501 Chipeta Way, Salt Lake City, UT 84108, USA.
Neurologic clinics
|July 5, 2023
概括
死亡医疗援助 (MAID) 法律在全球范围内有所不同,这影响了神经系统疾病患者的资格. 认知障碍,就像阿尔茨海默氏症痴呆症一样,由于不断变化的终端状态和决策能力,对MAID访问提出了独特的挑战.
科学领域:
- 医学伦理 医学伦理
- 神经学 神经学
- 公共卫生政策 公共卫生政策
背景情况:
- 医疗协助死亡 (MAID) 越来越多地在各个司法管辖区合法化.
- 在MAID程序和资格标准中存在显著的差异.
- 神经系统疾病经常是美国寻求MAID的原因.
研究的目的:
- 检查神经疾病患者的MAID资格的复杂性.
- 突出认知障碍患者面临的挑战,如阿尔茨海默氏症痴呆症,在访问MAID.
主要方法:
- 审查当前的MAID立法和资格框架.
- 分析涉及神经疾病和MAID请求的案例研究.
- 审查有关决策能力的伦理和法律考虑.
主要成果:
- 根据MAID的资格标准,经常会排除患有进展性神经疾病的个体.
- "绝症"要求对没有立即终止生命的疾病构成障碍.
- 像阿尔茨海默氏症痴呆症这样的疾病晚期决策能力受损使MAID访问复杂化.
结论:
- 当前的MAID框架可能无法充分满足患有进展性神经系统疾病的个体的需求.
- 需要进一步完善MAID政策,以平衡患者自主权与认知衰退患者的保障.
- MAID不断变化的格局需要持续的伦理和法律话语,特别是对于影响认知的条件.
相关概念视频
Drug Delivery: Parenteral Route
637
The parenteral route is a critical method of drug administration. It delivers compounds directly into the systemic circulation and bypasses the gastrointestinal tract. This approach is particularly advantageous for drugs that exhibit poor absorption or instability when administered orally.
There are three primary parenteral routes: intravenous (IV), intramuscular (IM), and subcutaneous (SC). The IV route introduces the drug directly into the bloodstream, ensuring immediate action. The IM route...
There are three primary parenteral routes: intravenous (IV), intramuscular (IM), and subcutaneous (SC). The IV route introduces the drug directly into the bloodstream, ensuring immediate action. The IM route...
637
Alzheimer's Disease: Treatment
220
Alzheimer's Disease (AD), a neurodegenerative disorder, is pathologically identified by amyloid plaques and neurofibrillary tangles composed of tau protein. AD pharmacotherapy aims to manage cognitive symptoms, delay disease progression, and treat behavioral symptoms. The treatment is primarily symptomatic and palliative, with no definitive disease-modifying therapy available. Cholinesterase inhibitors, including donepezil (Aricept), rivastigmine (Exelon), and galantamine (Razadyne), are...
220
Parkinson's Disease: Treatment
302
Neurodegenerative disorders, such as Parkinson's Disease (PD), involve the gradual and irreversible destruction of neurons in particular brain areas. These disorders exhibit standard features like proteinopathies, selective vulnerability of some neurons, and an interaction of intrinsic properties, genetics, and environmental influences in neural injury.
Parkinson's Disease is primarily a result of the loss of dopaminergic neurons in the substantia nigra pars compacta. The cornerstone of...
Parkinson's Disease is primarily a result of the loss of dopaminergic neurons in the substantia nigra pars compacta. The cornerstone of...
302
Continuing Care
1.5K
Continuing care describes the variety of health, personal, and social services provided over a prolonged period. The need for continuing care is increasing because people are living longer. Many people do not have families or others to care for them. Continuing care is mainly for patients who are disabled, functionally dependent, or suffering from a terminal disease. It is available within institutional settings or in homes. Examples include nursing centers or facilities, assisted living,...
1.5K
Neural Regulation
39.6K
Digestion begins with a cephalic phase that prepares the digestive system to receive food. When our brain processes visual or olfactory information about food, it triggers impulses in the cranial nerves innervating the salivary glands and stomach to prepare for food.
39.6K
Parkinson's Disease: Overview
606
Neurodegenerative disorders are progressive diseases that cause irreversible damage and loss to neurons in specific brain areas. Examples of these disorders include Parkinson's disease, Alzheimer's disease, Multiple Sclerosis (MS), and Amyotrophic Lateral Sclerosis (ALS). These disorders share characteristics such as proteinopathies, selective neuronal vulnerability, and a complex interplay between genetic and environmental factors. The primary therapeutic goal for these conditions is...
606

